Locate your nearest distributor

Text search:
Forgot password?
At BIOHIT HealthCare we believe that Innovation is key to driving change and through our academic and clinical relationships we specialise in transferring successful research applications into routine clinical use. The key objective of our diagnostics business is to prevent diseases of the gastrointestinal tract.

BIOHIT HealthCare brings products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the GastroPanel® blood test which diagnosis of stomach illnesses and associated risks. As a primary test for dyspeptic patient GastroPanel® helps prioritise patients who require referrals for Gastroscopy in Primary Care and Screening settings. 

Similarly, for the lower gastrointestinal tract, BIOHIT has a core focus on Irritable bowel syndrome and Inflammatory Bowel Disease. Throughout our website you will find a comprehensive range of some of the most cutting edge, innovative and effective tools for the diagnosis and management of these conditions, such as therapeutic drug monitoring assays for biological therapies and microbiota analysis tests for patients with dysbiosis.
BIOHIT's range of Quick Tests for Endoscopy, GP practices and clinic settings enable the fast and effective diagnosis of lactose intolerance and Helicobacter pylori infection, IBS/IBD, Colorectal cancer and coeliac disease. BIOHIT's quick tests are class leading, competitive and deliver real benefits to patients and clinicians.

Acetaldehyde elimination is another core area of BIOHIT's investment as we strive to reduce the global impact of this ubiquitous group I Carcinogen. The Acetium innovations were developed to reduce carcinogenic acetaldehyde in the gastrointestinal tract. You can read more about Acetaldehyde in our dedicated website www.acetium.com 

Groundbreaking Diagnostics

Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit’s mission is “Innovating for Health”.

Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit’s Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki since 1999, Small cap/Healthcare.

Read more

Study Protocols

BIOHIT writes and shares study protocols, i.e. descriptions of clinical studies designed to help validate and adopt Biohit Oyj’s products into routine healthcare settings. Our scientific advisory board supports research and development worldwide and assists with the evaluations of the therapeutic efficacy of Biohit’s Acetium capsule and lozenge products in current and novel clinical indications.

Read more

Innovation and Products

BIOHIT's innovations include products and services that are safe, ethical and cost efficient for screening, diagnosing, monitoring and preventing gastrointestinal diseases and associated risks.

Read more